INTRODUCTION

87
IGF1 is a circulating endocrine hormone that is a major regulator of organismal growth and Signaling #3027; 1:1000), pAkt S473 (Cell Signaling #4060; 1:1000), total Akt (Cell Signaling 162 #9272; 1:1000), E-cadherin (BD Biosciences #610182; 1:1000), and β-actin (Sigma #A5441; 163 1:5000). Membranes were incubated in LiCor secondary antibodies for 1 hour (anti-rabbit 164 800CW [LiCor #926-32211] ; anti-mouse 680LT [LiCor #925-68020]; 1:10,000), and imaged with 165 Odyssey Infrared Imager.
166
IGF1-induced cell cycle and viability analysis 167
For cell cycle: MCF-7 and ZR75.1 cells were reverse transfected as described above, serum 168 starved for approx. 30 hours, and pulsed with 10nM IGF1 for 17 hours. Cells were fixed in 70%
169
EtOH for 30 minutes at 4˚C and RNA digested using 50ng/ul RNase A (Qiagen #1007885) for 170 15 minutes at 37˚C. DNA content was then stained using 50ng/ul propidium iodide (Sigma 171 #P4170) for 30 minutes at 4˚C. Cell cycle profiles were analyzed using the BD LSRII flow 172 cytometer and analyzed using the FACS DIVA software. The statistical difference in percent of 173 cells in S-or G2/M phase in IGF1 treated cells over vehicle control in experimental groups was 174 evaluated using a two-tailed student's t-test (p<0.05).
175
For viability: T47D shSCR and shCDH1 #1 and #2 cells were plated in serum-free media in 96 176 well plates (9,000 cells/well) and then stimulated with IGF1 (10nM) for 6 days. The FluoReporter 177 Blue Fluorometric dsDNA Quantitation Kit was used to measure DNA content. Statistical 178 difference in Hoechst fluorescence in IGF1 treated cells over vehicle control in each cell line 179 was evaluated using a two-tailed student's t-test (p<0.05).
180
Immunofluorescence and Proximity ligation assay (PLA) 181 Cells were plated on coverslips and fixed in 4% paraformaldehyde for 30 minutes at 37˚C.
182
Coverslips were permeabilized for 1 hour using PBS+0.3% Triton X-100. For Technologies #A11018]; 1:200). For in situ proximity ligation assay, coverslips were processed 188 using the Duolink Red mouse/rabbit kit using the protocol provided (Sigma #DUO92101) with 189 the antibody dilutions above. The ratio of puncta/nuclei for each experimental condition was 190 calculated by counting all puncta and nuclei in five 60x images. One-way ANOVA was used to 191 compare the ratios between the experimental conditions (VHC, 30m, 6hr, 24hr showed increased IGF1R and Akt phosphorylation compared to control ( Fig 1D) . Additionally,
248
we evaluated confluency-dependent IGF1R signaling to understand the effect of increased cell-249 cell contacts. A confluent monolayer of MCF-7 cells lost the ability to initiate IGF1R signaling 250 upon ligand stimulation compared to a sub-confluent monolayer (approx. 40-50%), however, the 251 knockdown of E-cadherin rescued signaling in both confluency conditions ( Fig 1E) .
252
We evaluated the functional effect of enhanced IGF1 signaling on the cell cycle profile in MCF-7 253 and ZR75.1 cells with reduced E-cadherin. CDH1 knockdown cells showed a significant 254 increase (p=0.03 and p=0.0005, respectively) in the percentage of cells progressing into the S-255 and G2/M-phases of the cell cycle following IGF1 treatment compared to siSCR cells ( Fig 1F) .
256
Similarly, slight increases in IGF1-induced cell viability in siCDH1 compared to siSCR in T47D 257 cells were observed ( Fig S1) .
258
We overexpressed E-cadherin in MDA-MB-231 cells, an ER-negative IDC cell line with 273 and ULA (p=0.0003; Fig 2B) growth conditions resulting in a shift in the EC 50 . Additionally,
274
ZR75.1 siCDH1 cells showed significantly decreased viability and a shift in the EC 50 when 275 grown in ULA (p<0.0001; Fig S3) in response to OSI treatment, but not in the 2D growth 276 condition. Similarly, MCF-7 siCDH1 cells showed decreased viability in response to BMS 277 compared to siSCR cells the ULA growth condition (p<0.0001), but no significant difference in 278 2D ( Fig 2C-D) . Overall, these data suggest that the loss of E-cadherin enhances breast cancer 279 cell sensitivity to IGF1R inhibition. We also tested the growth response of MCF-7 siSCR and 280 siCDH1 cells treated with ICI 182,780 (ICI), a selective estrogen receptor downregulator 281 (SERD), and observed no statistical difference in EC 50 suggesting that the loss of E-cadherin 282 does not generally sensitize cells to all small molecule drug treatments ( Fig S4) . using each primary antibody alone and a no primary antibody control and did not detect 296 significant levels of PLA puncta over background ( Fig S5D-F) . The interaction between IGF1R 297 and E-cadherin following IGF1 stimulation was examined using PLA. In MCF-7 cells, IGF1 298 treatment caused a significant decrease in number of fluorescent puncta (p=0.003), suggesting 299 that the interaction between the two proteins needs to be disrupted for proper IGF1R function 
302
We stained MCF-7 cells for endogenous IGF1R and E-cadherin and determined that IGF1R and 303 E-cadherin co-localize to adherens junctions. Interestingly, co-localization was prominent at the 304 points of cell-cell contact, and noticeably absent or reduced on portions of the membrane where 305 there was no cell-cell contact ( Fig 3J) . This suggests that E-cadherin recruits IGF1R to 306 adherens junctions, perhaps to sequester the receptor as a mechanism of signaling repression.
307
Upon knockdown of E-cadherin the expression pattern of IGF1R appears to redistribute equally 308 to the entire cell membrane ( Fig 3K) supporting the idea that E-cadherin influences and 309 regulates IGF1R localization.
Invasive lobular breast cancers (ILC) display enhanced IGF1-IGF1R pathway activation 311
Because knockdown or inhibition of E-cadherin induces hyperactivity of the IGF1R pathway in 312 cell line models, we investigated whether IGF1R pathway activity is also hyperactivated in ILC, 313 a subtype of breast cancer that accounts for 10-15% of all breast cancer cases and is 314 molecularly classified by its genetic loss of E-cadherin 23 . Because 90-95% of ILC tumors are 315 ER+, we focused on this cohort 23 . IGF1R expression and localization was examined in the ER+ 316 ILC cell lines: MDA-MB-134 (MM134; Fig 4A) , SUM44PE ( Fig 4B) , and BCK4 ( Fig 4C) . IGF1R 317 staining was membranous similar to that observed in MCF-7 siCDH1 cells ( Fig 3F) . As 318 expected, ILC cells showed a lack of membranous E-cadherin staining ( Fig 4A-C) .
319
To compare IGF1R activity in ER+ ILC and IDC tumors, CDH1 and IGF1 ligand mRNA 320 expression, and IGF1R phosphorylation (pIGF1R; Y1135/Y1136) were examined using RNA-321 sequencing and Reverse Phase Protein Array data from The Cancer Genome Atlas (TCGA).
322
Concurrent with a decrease in CDH1 mRNA expression (p=9.06e-52; Fig 4D) , IGF1 ligand 323 mRNA expression (p=1.3e-15; Fig 4E) and pIGF1R levels (p=2.15e-08; Fig 4F) were 324 significantly increased in the ILC tumors compared to IDC tumors. Interestingly, ILC tumors 325 exhibited a significant positive correlation between IGF1 mRNA expression and pIGF1R level 326 (Spearman rho=0.21; p=0.012), despite having significantly reduced total IGF1R expression 327 compared to IDC (data not shown; Fig 4G) . In contrast, IDC tumors did not show a correlation 328 (Spearman rho=0.06; p=0.22) suggesting that presence of IGF1 ligand did not necessarily 329 activate IGF1R in IDC. Strikingly, the percentage of tumors with higher than median expression 330 (across all breast tumors) of both IGF1 and pIGF1R is significantly higher in ILC (56.2%) 331 compared to IDC (21.3%), suggesting that IGF1 ligand activates IGF1R signaling in these 332 tumors more efficiently with the loss of E-cadherin (chi-square test, p= 2.5e-14 [ Fig 4G] ).
333
Interestingly, when assessing activation of the IGF-sig 16 in ER+ ILC versus IDC in the TCGA 334 cohort we did not observe a difference in expression score (data not shown).
IGF1R inhibitors and endocrine therapy synergize to decrease viability in ILC cells
336
Clinically, patients with ER+ ILC are treated with endocrine therapy targeting ER, however, data 337 from the BIG 1-98 trial suggest that ILC tumors demonstrate resistance to tamoxifen, a selective 338 estrogen receptor modulator, compared to IDC 29 . Additionally, results from multiple clinical 339 studies indicate that ILC patients have a poorer prognosis with more frequent late recurrences 340 compared to IDC 30-32 . This highlights the need to improve therapeutic options in ILC patients 341 based on uniquely activated pathways and therefore, we evaluated efficacy of IGF1R pathway 342 inhibitors in ER+ ILC cell lines in combination with endocrine therapy. Recent data published 343 from our lab suggest that tamoxifen, can act as a partial ER agonist activating ER activity in 344 some ILC cell lines, rather than a pure antagonist as in IDC cells 33 , in line with the data from the 345 BIG1-98 study. Therefore, we tested efficacy of the selective estrogen receptor downregulator,
346
ICI 182,780 (ICI) in combination with two IGF1R inhibitors used in Figure 2 (OSI and BMS) and 347 a PI3K/mTOR inhibitor (BEZ235 [BEZ] ). SUM44PE and MM134 cells were treated with 348 increasing doses of OSI ( Fig 5A-B; Fig S6A-B) , BMS (Fig 5C-D; Fig S6C-D) , and BEZ ( Fig 5E- 
354
ED90 indicating a high level of synergy for the three sets of inhibitor combinations (Fig 5, Fig   355   S6 , Table S1 ). The lowest CI values were observed for the BMS+ICI drug combination in 356 SUM44PE cells (ED50=0.127, ED75=0.081, ED90=0.099). Additionally, a minimum dose 357 reduction index (DRI) for ICI of 8-fold for all drug combinations in SUM44PE cells and 2-fold in 358 MM134 cells at the EC50 was seen. This data suggests that adding an IGF1R pathway inhibitor in combination with ICI reduces the concentration of ICI necessary to achieve that same 360 inhibitory effect as ICI alone. collected and stained for Ki67 as a marker of proliferation. We observed a significant decrease 373 in Ki67 positive nuclei in both tumor models treated with BMS ( Fig 6) . In the MM134 tumor we 374 observed a significant decrease (p=0.002) in Ki67 positive nuclei from 47% in the vehicle to 375 22% in the BMS treated tumor tissue (n=3 or 4; Fig 6A-C) . Similarly, in the BCK4 tumor we 376 observed a significant decrease (p=0.005) in Ki67 positive nuclei from 25% in the vehicle to 377 11% in the BMS treated tumor tissue (n=6; Fig 6D-F) . This data suggest that targeting IGF1R in 378 ILC tumors may be a useful strategy to inhibit cell proliferation.
380
DISCUSSION
381
Despite a large body of preclinical evidence supporting the use of IGF1R inhibitors for the 382 treatment of breast cancer, the outcomes of clinical trials testing the efficacy of these drugs in 383 patients thus far have been disappointing. However, these trials proceeded with a lack of appropriate biomarkers for predicting positive therapeutic efficacy and little to no understanding 385 of which tumor types would benefit [13] [14] [15] 38 . In response, in recent years the field has emphasized 386 the need to understand and identify gene expression or proteomic biomarkers that predict a 387 positive response to targeted therapy. Along this thought process, we previously published a 388 gene expression signature used to identify tumors that are IGF1 responsive 16 and here we focus 389 on one proteomic biomarker, E-cadherin, identified through an integrative computational 390 approach recently published by our group 17 . It is known that constitutive IGF1R activation drives 391 E-cadherin transcriptional repression through EMT 6,10 , however, the reverse regulation of IGF1R 392 by E-cadherin has not been previously characterized. Our data suggest that loss of E-cadherin 393 in breast tumors, specifically in ILC, highlights a subset of tumors that may be responsive to 394 IGF1R inhibition and here we begin to describe the mechanism by which this regulation occurs.
395
We demonstrate that in breast cancer cells, IGF1R is endogenously localized to cell-cell 396 contacts, similar to data published in MCF-7 cells overexpressing IGF1R 39 and in corneal 397 epithelial cells 40 . We show a direct, endogenous interaction between IGF1R and E-cadherin 398 using in situ proximity ligation assay. To our knowledge interaction between IGF1R and E-399 cadherin in breast cancer cells has only been demonstrated by immunoprecipitation (IP) 39 . Our 400 data provide confirmation of this interaction using a technique known to be higher in specificity 401 and sensitivity compared to IP, which requires intense cell manipulation (e.g. lysis and scraping) 402 and often results in pull-down of entire protein complexes. This suggests that IGF1R is recruited 403 to adherens junctions by E-cadherin, possibly resulting in receptor sequestration and signaling 404 repression. This process is similar to the sequestration of EGFR into the adherens junction and 405 loss of receptor mobility, a well characterized mechanism of EGFR signaling repression 41-43 .
406
However, data published by Curto et al. suggests that the latter action is mediated through the 407 tumor suppressor, Merlin, responsible for coordinating stabilization of the adherens junction and 408 thereby regulating contact-inhibition growth 43 . Although IGF1R signaling is controlled in a contact-dependent manner (Fig 1E) , they also showed that IGF1 activity is not regulated by 410 Merlin, indicating that IGF1R regulation by E-cadherin likely occurs independent of this factor 43 .
411
Although there may be a yet undefined intermediate regulator similar to Merlin, our data indicate 412 that E-cadherin plays a role in coordinating the recruitment and sequestration of IGF1R within 413 the adherens junction to repress IGF1R signaling. When E-cadherin is lost and junction 414 formation is disrupted (such as in ILC cells), IGF1R is released and re-localizes to the entirety of 415 the cell membrane where signaling is more easily initiated upon IGF1 ligand binding.
416
Supporting this concept, our data indicate that the knockdown of E-cadherin in three ER+ breast 417 cancer cell lines not only enhanced IGF1-induced signaling via IGF1R but also increased 418 sensitivity of the cells to the ligand. This is similar to the relationship reported between EGF-
419
EGFR and IGF1-IGF1R upon adherens junction disruption via calcium-depletion 41 . Because of 420 the increased IGF1R pathway activation associated with the loss of E-cadherin, the knockdown 421 cells in turn became more sensitive to IGF1R inhibition.
422
We believe that IGF1R signaling may be particularly important in ILC, an understudied subtype 423 of breast cancer, due to the complete loss of E-cadherin protein and/or adherens junction 424 formation. In this subtype, the loss of E-cadherin may serve as a biomarker of IGF1 activity.
425
Indeed, we demonstrate that ILC have increased IGF1R pathway activation (IGF1 ligand 426 expression and pIGF1R levels) compared with IDC. This is similar to the results of two studies 427 analyzing differences between ILC and IDC that found increased IGF1 ligand and IGF1R 428 expression levels in ILC 44, 45 . Consistent with this, we found that ILC cell lines are susceptible to 429 IGF1R inhibition and importantly, that IGF1R pathway inhibitors (OSI, BMS, BEZ) synergize with 430 a standard of care endocrine therapy (ICI) resulting in further reduced cell growth. Future 431 studies will focus on validating these therapies in additional ILC tumors and understanding the 432 synergistic interaction between IGF1R inhibitors and ICI. This data may be especially important 433 given that there is an increased prevalence of late recurrences in ER+ ILC compared to ER+ IDC tumors treated with endocrine therapy, indicating the need for improved therapy options for 435 patients with ILC 29,30 .
436
One limitation for the use of IGF1R inhibitors in ILC is the relatively high prevalence of 
454
In summary, we present a diverse set of data indicating that the loss of E-cadherin enhances 455 IGF1R pathway activity and sensitivity to IGF1R therapy, specifically in ILC. We show that 456 IGF1R and E-cadherin directly interact, which leads to the sequestration and potential 457 repression of IGF1R within the adherens junction. Overall, this study begins to shed light on a 458 previously unrecognized mechanism of IGF1R regulation by E-cadherin and highlights a 459 potential therapeutic strategy of exploiting IGF1R pathway activity in ILC tumors. angiogenesis. Cancer Cell 10, 437-449 (2006 
